Dendreon CEO Mitch Gold: Seattle Biotech Has An Anchor Tenant Again - Xconomy

  • email Email to a friend
  • print Print version

Did you enjoy this article?

(total 0 votes)
Try our own cheap Booking Service15 times read : Adjust font size: Decrease font Enlarge font
image

The impact of today’s FDA approval of Dendreon’s prostate cancer drug is being covered exhaustively from every angle on the Web. There’s the company saga , the benefit for prostate cancer patients, the boost to the field of cancer immunotherapy ...

Read this article...



Post your comment comment Comments (0 posted)

copyright